Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Controversies in the Management of AML in Older Patients: A Canadian Perspective.

Current oncology (Toronto, Ont.) - 18 Jul 2026

Schuh Andre C, Brandwein Joseph, Elsawy Mahmoud, Sanford David, Leber Brian

Abstract excerpt

In the companion article in this issue of Current Oncology, 'Management of AML in Older Patients: An Updated Canadian Consensus', the authors have presented the third iteration of Canadian consensus guidelines on AML treatment in the elderly. While many aspects of AML treatment in the elderly have become better defined, some old questions remain and new questions and controversies have arisen. Here, we address...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Canada
Share to fms-Like Tyrosine Kinase 3

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to NPM1 gene

Share to Isocitrate Dehydrogenase

Share to Leukemia, Myeloid, Acute

Share to Mutation

Share to Nucleophosmin

Source

Open in PubMed Open full text

Identifiers

PMID: 42505233
DOI: 10.3390/curroncol33070431
PMCID: PMC13408529

Genes

FLT3
IDH1
TP53
NPM1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 24 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Controversies in the Management of AML in Older Patients: A Canadian Perspective.PMID 42505233Read ↗

AML in the Elderly - When less may be more.Semantic proximity Read ↗

A scoring system for AML patients aged 70 years or older, eligible for intensive chemotherapy: a study based on a large European data set using the DATAML, SAL, and PETHEMA registries.Semantic proximity Read ↗

Age-dependent clinical, molecular, and prognostic differences in patients with AML: a retrospective study.Semantic proximity Read ↗

Latest Insights and Progress in the Clinical Management of Elderly Patients with Acute Myeloid Leukemia: From Genetic Advancements to Targeted TreatmentsSemantic proximity Read ↗

Advancements and Challenges in the Treatment of AML.Semantic proximity Read ↗

Genetics of acute myeloid leukemia in the elderly: mutation spectrum and clinical impact in intensively treated patients aged 75 years or older.Semantic proximity Read ↗

A precision medicine approach to management of acute myeloid leukemia in older adults.Semantic proximity Read ↗

Prognostic Implications and Therapeutic Landscape of IDH1-Mutated AML: An Updated Review of Evidence and Indian Perspective.Semantic proximity Read ↗

Prognostic significance of NPM1 mutations in the absence of FLT3-internal tandem duplication in older patients with acute myeloid leukemia: a SWOG and UK National Cancer Research Institute/Medical Research Council report.Semantic proximity Read ↗

Acute myeloid leukemia: 2014 update on risk-stratification and management.Semantic proximity Read ↗

Characteristics, clinical outcome, and prognostic significance of IDH mutations in AML.Semantic proximity Read ↗

Study Offers Insights on Prognostic Significance of IDH Mutations Across Age Groups in AML.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.